Glura MP 500 Tablet SR is a combination oral antidiabetic medication containing Metformin (500 mg), Pioglitazone (15 mg), and Sitagliptin (100 mg), formulated as a sustained-release tablet to optimize glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, thereby promoting glucose-dependent insulin secretion and decreasing glucagon release. The synergistic action of these agents targets multiple pathophysiological defects of type 2 diabetes, facilitating improved glycemic control. Glura MP 500 Tablet SR is indicated as adjunctive therapy to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The sustained-release formulation allows for once-daily dosing, enhancing patient compliance. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Common adverse effects may include gastrointestinal disturbances, weight gain, and hypoglycemia, particularly when used with other antidiabetic agents. Use is contraindicated in patients with severe renal impairment, hepatic dysfunction, or known hypersensitivity to any component.